Losing Weight for Less $$$ & You Can’t Pay Pe...

#907: The U.S. economy unexpectedly lost 23,000 jobs in July – a sharp miss from economists' expectation of an 83,000-job gain. Plus, more than 5,000 investors are still copying Leopold Aschenbrenner's trades, despite his hedge fund's meltdown. Burger King overtakes Wendy's as th ...  Show more

#906: Bank of America is spending $250M a year on GLP-1 weight loss drugs for its employees. SpaceX's first post-IPO lockup expired Thursday after releasing 912 million restricted shares into the public market. A group of 20 undergraduate students at Indiana University's Kelley S ...  Show more

Eli Lilly and Novo Nordisk can’t keep up with demand for their weight loss medications. In this Viewsroom podcast, Breakingviews columnists discuss the hype among celebrities, the different approaches to prescribing them in the US and Europe, and how they can reshape the world. V ...  Show more

 Bloomberg News Health Reporter Madison Muller explains how Pfizer’s second weight-loss setback this year is a warning sign that breaking into the lucrative obesity market isn’t going to be easy. Cory Klippsten, CEO at Swan Bitcoin, shares his crypto outlook for 2024. Benjamin Wo ...  Show more

Bloomberg News Health Reporter Madison Muller discusses how the drug Ozempic could cut demand for big-money drugs targeting a wide range of maladies, even Alzheimer’s. Hosts: Carol Massar and Tim Stenovec. Producer: Paul Brennan.See omnystudio.com/listener for privacy information ...  Show more

In the past couple years, demand has gone wild for drugs like Ozempic – and its cousins, Zepbound, Wegovy, and Mounjaro. For people who had never been able to lose weight before, suddenly the numbers on the scale were plummeting. And everybody wanted to get their hands on them. N ...  Show more